prs-343
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 28, 2017 (NCT03330561)
Timeline
Indications
Mechanism of action
ERBB2 inhibitor
TNFRSF9 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05190445 | Phase 2 | Nov 1, 2021 | Pieris Pharmaceuticals GmbH |
| NCT03650348 | Phase 1 | Aug 21, 2018 | Pieris Pharmaceuticals GmbH |
| NCT03330561 | Phase 1 | Sep 28, 2017 | Pieris Pharmaceuticals GmbH |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pieris Pharmaceuticals GmbH | For profit | 3 | 3 | 2 | 2017 |
1 organizations
Page 1 / 1